First mRNA vaccine for acne enters human testing
NCT ID NCT07013747
Summary
This early-stage study is testing a new mRNA vaccine designed to help control mild acne. About 120 healthy adults aged 18-45 with mild facial acne will receive two shots of either the vaccine or a placebo. Researchers will track safety, side effects, and whether the vaccine reduces the number of acne lesions on the face over a core study period and an optional 30-month follow-up.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ACNE are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
DelRicht Research- Site Number : 8400003
RECRUITINGNew Orleans, Louisiana, 70115, United States
-
Encino Research Center- Site Number : 8400008
RECRUITINGEncino, California, 91436, United States
-
Encore Research Group-Jacksonville Center for Clinical Research- Site Number : 8400006
RECRUITINGJacksonville, Florida, 32216, United States
-
Moore Clinical Research - Brandon- Site Number : 8400007
RECRUITINGBrandon, Florida, 33511, United States
Conditions
Explore the condition pages connected to this study.